clinical trial · NCT07305831
A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012)
Merck Sharp & Dohme LLC·phase1·completed·n = 62
HealthyUlonivirineMoxifloxacinUlonivirine PlaceboMoxifloxacin Placebo
brief summary
Researchers are looking for new treatments for HIV-1 (human immunodeficiency virus type 1) that are safe, well-tolerated, and can be taken less often. HIV-1 is the most common type of HIV, which is a virus that attacks cells of the immune system. Ulonivirine (MK-8507) is a study medicine designed to treat HIV-1 The goal of this study is to learn if ulonivirine does not increase the QT interval (a measure of heart rhythm on an electrocardiogram) above a certain amount. Researchers also want to learn what happens to the amount of ulonivirine in a healthy person's body over time.
started
Jan 22, 2026
primary completion
Apr 9, 2026
completion
Apr 9, 2026
last updated
Apr 21, 2026
official title
A Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of MK-8507 on the QTc Interval in Healthy Adult Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol